New Research Identifies Need for Patient-Centric Clinical Trials and Role for CROs
New Research Identifies Patient-centric Strategies for Clinical Development with over 125 Global Research Opinion Leaders.
Menlo Park, CA, April 28, 2017 --(PR.com)-- Life Science Strategy Group (LSSG) the leading strategic consulting firm to the CRO industry, is pleased to announce the results of a new 2017 study, "Patient-Centric Clinical Development Status and the Role of the Contract Research Organization (CRO)." which focuses on the current status and emerging trends of patient-centric clinical trials and the role CROs will play.
Recognizing the upcoming need of distinct patient populations and understanding how CROs can play a role in running patient-centric trials, Life Science Strategy Group (LSSG) conducted research with 126 global opinion leaders involved in preclinical and clinical research at small, mid-sized, and large biopharmaceutical companies. LSSG found that up to 87% of respondents are discussing patient-centric approaches to clinical development, with half of the surveyed companies expecting to implement patient-centric approaches for clinical development within the next 1-3 years.
"It is important to realize where Pharma is in its implementation of patient-centric strategies for clinical development today and to understand their needs in the future," said Jon Meyer, Life Science Strategy Group’s CRO Industry Practice Leader.
Further, the research identifies that CROs need to play an increasing role as an enabler of success in patient-centric clinical trials. "Sponsors would like to see CROs research new and existing technologies such as data collection devices, patient-oriented websites and applications, and sample storage options, that enhance patient-centric trial approaches. This study gives us a glimpse at which CROs are best prepared to meet Pharma’s needs today and in the future," said Meyer.
To learn more about LSSG’s new study examining patient-centric development trends as well as which CROs such as Covance, ICON, inVentiv Health Clinical, INC Research, Parexel, PPD, PRA International and QuintilesIMS are best prepared to address the new development needs, please contact Life Science Strategy Group or click on the link below.
http://lifesciencestrategy.com/publications/cro-industry/pubs-cro-patient-centric-april-2017/
About Life Science Strategy Group, LLC
Life Science Strategy Group, LLC specializes in strategic consulting and market research engagements across a variety of therapeutic, technology and service industries including contract research services, pharmaceutical, biotechnology, medical devices, diagnostics and drug discovery.
Recognizing the upcoming need of distinct patient populations and understanding how CROs can play a role in running patient-centric trials, Life Science Strategy Group (LSSG) conducted research with 126 global opinion leaders involved in preclinical and clinical research at small, mid-sized, and large biopharmaceutical companies. LSSG found that up to 87% of respondents are discussing patient-centric approaches to clinical development, with half of the surveyed companies expecting to implement patient-centric approaches for clinical development within the next 1-3 years.
"It is important to realize where Pharma is in its implementation of patient-centric strategies for clinical development today and to understand their needs in the future," said Jon Meyer, Life Science Strategy Group’s CRO Industry Practice Leader.
Further, the research identifies that CROs need to play an increasing role as an enabler of success in patient-centric clinical trials. "Sponsors would like to see CROs research new and existing technologies such as data collection devices, patient-oriented websites and applications, and sample storage options, that enhance patient-centric trial approaches. This study gives us a glimpse at which CROs are best prepared to meet Pharma’s needs today and in the future," said Meyer.
To learn more about LSSG’s new study examining patient-centric development trends as well as which CROs such as Covance, ICON, inVentiv Health Clinical, INC Research, Parexel, PPD, PRA International and QuintilesIMS are best prepared to address the new development needs, please contact Life Science Strategy Group or click on the link below.
http://lifesciencestrategy.com/publications/cro-industry/pubs-cro-patient-centric-april-2017/
About Life Science Strategy Group, LLC
Life Science Strategy Group, LLC specializes in strategic consulting and market research engagements across a variety of therapeutic, technology and service industries including contract research services, pharmaceutical, biotechnology, medical devices, diagnostics and drug discovery.
Contact
Life Science Strategy Group, LLC
Jon Meyer
1-800-941-6373
www.lifesciencestrategy.com
Jon Meyer
1-800-941-6373
www.lifesciencestrategy.com
Contact
Categories